AstraZeneca (LSE:AZN) is navigating a period of robust growth and strategic challenges. Recent developments include an 18% ...

AIM ImmunoTech (AIM) reported positive preliminary data from the Phase 1b/2 study evaluating the combination of Ampligen and ...

Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ETCompany ParticipantsPascal Soriot - Chief ...

While none of the experimental combinations met efficacy targets, durvalumab with monalizumab and ceralasertib showed ...

Imfinzi is a human monoclonal antibody that targets the PD-L1 protein, whereas Imjudo focuses on the CTLA-4 protein.

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

The adaptive basket trial, which matches patients to treatments based on complex biomarker signatures, could help shape ...

Patients with limited-stage small cell lung cancer saw improvements in progression-free survival and overall survival with ...

AstraZeneca said that about 20% of patients treated with the Stride regimen, which is a single dose of Imjudo added to Imfinzi, were alive at five years, compared to 9.4% of those treated with ...

In a result that's likely to change how some bladder cancer patients get care, AstraZeneca said that its drug Imfinzi boosted patient survival alongside chemotherapy and surgery. Two years after ...

Adding perioperative durvalumab (Imfinzi) to neoadjuvant chemotherapy significantly improved survival outcomes in ...